Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Pain
Published in: Molecular Pain 1/2009

Open Access 01-12-2009 | Research

Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue

Authors: Stephen MF Jamieson, Joshuan Subramaniam, Johnson J Liu, Nancy N Jong, Virginia Ip, Bronwen Connor, Mark J McKeage

Published in: Molecular Pain | Issue 1/2009

Login to get access

Abstract

Background

Oxaliplatin and related chemotherapeutic drugs cause painful chronic peripheral neuropathies in cancer patients. We investigated changes in neuronal size profiles and neurofilament immunoreactivity in L5 dorsal root ganglion (DRG) tissue of adult female Wistar rats after multiple-dose treatment with oxaliplatin, cisplatin, carboplatin or paclitaxel.

Results

After treatment with oxaliplatin, phosphorylated neurofilament heavy subunit (pNF-H) immunoreactivity was reduced in neuronal cell bodies, but unchanged in nerve fibres, of the L5 DRG. Morphometric analysis confirmed significant changes in the number (-75%; P < 0.0002) and size (-45%; P < 0.0001) of pNF-H-immunoreactive neurons after oxaliplatin treatment. pNF-H-immunoreactive neurons had overlapping size profiles and co-localisation with neurons displaying cell body immunoreactivity for parvalbumin, non-phospho-specific neurofilament medium subunit (NF-M) and non-phospho-specific neurofilament heavy subunit (NF-H), in control DRG. However, there were no significant changes in the numbers of neurons with immunoreactivity for parvalbumin (4.6%, P = 0.82), NF-M (-1%, P = 0.96) or NF-H (0%; P = 0.93) after oxaliplatin treatment, although the sizes of parvalbumin (-29%, P = 0.047), NF-M (-11%, P = 0.038) and NF-H (-28%; P = 0.0033) immunoreactive neurons were reduced. In an independent comparison of different chemotherapeutic agents, the number of pNF-H-immunoreactive neurons was significantly altered by oxaliplatin (-77.2%; P < 0.0001) and cisplatin (-35.2%; P = 0.03) but not by carboplatin or paclitaxel, and their mean cell body area was significantly changed by oxaliplatin (-31.1%; P = 0.008) but not by cisplatin, carboplatin or paclitaxel.

Conclusion

This study has demonstrated a specific pattern of loss of pNF-H immunoreactivity in rat DRG tissue that corresponds with the relative neurotoxicity of oxaliplatin, cisplatin and carboplatin. Loss of pNF-H may be mechanistically linked to oxaliplatin-induced neuronal atrophy, and serves as a readily measureable endpoint of its neurotoxicity in the rat model.
Appendix
Available only for authorised users
Literature
1.
O'Dwyer PJ, Johnson SW: Current status of oxaliplatin in colorectal cancer. Semin Oncol 2003,30(3 Suppl 6):78–87. 10.1016/S0093-7754(03)00215-XPubMedCrossRef
2.
Grothey A: Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003,30(4 Suppl 15):5–13. 10.1016/S0093-7754(03)00399-3PubMedCrossRef
3.
Extra JM, Marty M, Brienza S, Misset JL: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998,25(2 Suppl 5):13–22.PubMed
4.
Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002,20(7):1767–1774. 10.1200/JCO.2002.07.056PubMedCrossRef
5.
McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC: Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001,85(8):1219–1225. 10.1054/bjoc.2001.2024PubMedCentralPubMedCrossRef
6.
Ling B, Coudore-Civiale MA, Balayssac D, Eschalier A, Coudore F, Authier N: Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology 2007,234(3):176–184. 10.1016/j.tox.2007.02.013PubMedCrossRef
7.
Joseph EK, Chen X, Bogen O, Levine JD: Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 2008,9(5):463–472. 10.1016/j.jpain.2008.01.335PubMedCrossRef
8.
Jamieson SM, Liu J, Connor B, McKeage MJ: Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 2005,56(4):391–399. 10.1007/s00280-004-0953-4PubMedCrossRef
9.
Cavaletti G, Tredici G, Petruccioli MG, Donde E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Etienne GG: Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001,37(18):2457–2463. 10.1016/S0959-8049(01)00300-8PubMedCrossRef
10.
Ling B, Authier N, Balayssac D, Eschalier A, Coudore F: Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 2007,128(3):225–234. 10.1016/j.pain.2006.09.016PubMedCrossRef
11.
Ta LE, Low PA, Windebank AJ: Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 2009, 5: 9. 10.1186/1744-8069-5-9PubMedCentralPubMedCrossRef
12.
Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, Wyrick SD, Chaney SG: Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 1998,46(2):342–351.PubMed
13.
Liu J, Kraut EH, Balcerzak S, Grever M, D'Ambrosio S, Chan KK: Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat. Cancer Chemother Pharmacol 2002,50(6):445–453. 10.1007/s00280-002-0531-6PubMedCrossRef
14.
Ip V, McKeage MJ, Thompson P, Damianovich D, Findlay M, Liu JJ: Platinum-specific detection and quantification of oxaliplatin and Pt(R, R-diaminocyclohexane)Cl-2 in the blood plasma of colorectal cancer patients. Journal of Analytical Atomic Spectrometry 2008,23(6):881. 10.1039/b716925fCrossRef
15.
Liu JJ, Jamieson SM, Subramaniam J, Ip V, Jong NN, Mercer JF, McKeage MJ: Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother Pharmacol 2009,64(4):847–856. 10.1007/s00280-009-1017-6PubMedCrossRef
16.
Veeranna , Lee JH, Pareek TK, Jaffee H, Boland B, Vinod KY, Amin N, Kulkarni AB, Pant HC, Nixon RA: Neurofilament tail phosphorylation: identity of the RT-97 phosphoepitope and regulation in neurons by cross-talk among proline-directed kinases. J Neurochem 2008,107(1):35–49.PubMedCentralPubMed
17.
Lawson SN, Harper AA, Harper EI, Garson JA, Anderton BH: A monoclonal antibody against neurofilament protein specifically labels a subpopulation of rat sensory neurones. J Comp Neurol 1984,228(2):263–272. 10.1002/cne.902280211PubMedCrossRef
18.
Lawson SN, Waddell PJ: Soma neurofilament immunoreactivity is related to cell size and fibre conduction velocity in rat primary sensory neurons. J Physiol 1991, 435: 41–63.PubMedCentralPubMedCrossRef
19.
Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, Moreira PI, Zhua X, Smith MA, Perry G: Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 2004,61(24):3057–3075. 10.1007/s00018-004-4268-8PubMedCrossRef
20.
Carr PA, Yamamoto T, Karmy G, Baimbridge KG, Nagy JI: Analysis of parvalbumin and calbindin D28k-immunoreactive neurons in dorsal root ganglia of rat in relation to their cytochrome oxidase and carbonic anhydrase content. Neuroscience 1989,33(2):363–371. 10.1016/0306-4522(89)90216-9PubMedCrossRef
21.
Celio MR: Calbindin D-28k and parvalbumin in the rat nervous system. Neuroscience 1990,35(2):375–475. 10.1016/0306-4522(90)90091-HPubMedCrossRef
22.
Perry MJ, Lawson SN, Robertson J: Neurofilament immunoreactivity in populations of rat primary afferent neurons: a quantitative study of phosphorylated and non-phosphorylated subunits. J Neurocytol 1991,20(9):746–758. 10.1007/BF01187848PubMedCrossRef
23.
Screnci D, Er HM, Hambley TW, Galettis P, Brouwer W, McKeage MJ: Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer 1997,76(4):502–510.PubMedCentralPubMedCrossRef
24.
Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC: Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 2000,82(4):966–972. 10.1054/bjoc.1999.1026PubMedCentralPubMedCrossRef
25.
Jamieson SM, Liu JJ, Connor B, Dragunow M, McKeage MJ: Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. Neurotoxicology 2007,28(6):1092–1098. 10.1016/j.neuro.2007.04.009PubMedCrossRef
26.
27.
Fernyhough P, Gallagher A, Averill SA, Priestley JV, Hounsom L, Patel J, Tomlinson DR: Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 1999,48(4):881–889. 10.2337/diabetes.48.4.881PubMedCrossRef
28.
Gold BG, Austin DR: Regulation of aberrant neurofilament phosphorylation in neuronal perikarya. III. Alterations following single and continuous beta, beta'-iminodipropionitrile administrations. Brain Res 1991,563(1–2):151–162. 10.1016/0006-8993(91)91528-9PubMedCrossRef
29.
Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, et al.: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996,7(1):95–98.PubMedCrossRef
30.
Hoop RG, Burg ME, ten Bokkel Huinink WW, van Houwelingen C, Neijt JP: Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990,66(8):1697–1702. 10.1002/1097-0142(19901015)66:8<1697::AID-CNCR2820660808>3.0.CO;2-GPubMedCrossRef
31.
Canetta R, Rozencweig M, Carter SK: Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985,12(Suppl A):125–136. 10.1016/0305-7372(85)90027-1PubMedCrossRef
32.
Sakaguchi T, Okada M, Kitamura T, Kawasaki K: Reduced diameter and conduction velocity of myelinated fibers in the sciatic nerve of a neurofilament-deficient mutant quail. Neurosci Lett 1993,153(1):65–68. 10.1016/0304-3940(93)90078-YPubMedCrossRef
33.
Kriz J, Zhu Q, Julien JP, Padjen AL: Electrophysiological properties of axons in mice lacking neurofilament subunit genes: disparity between conduction velocity and axon diameter in absence of NF-H. Brain Res 2000,885(1):32–44. 10.1016/S0006-8993(00)02899-7PubMedCrossRef
34.
Parhad IM, Scott JN, Cellars LA, Bains JS, Krekoski CA, Clark AW: Axonal atrophy in aging is associated with a decline in neurofilament gene expression. J Neurosci Res 1995,41(3):355–366. 10.1002/jnr.490410308PubMedCrossRef
35.
Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005,4(4):307–320. 10.1038/nrd1691PubMedCrossRef
36.
McDonald ES, Randon KR, Knight A, Windebank AJ: Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005,18(2):305–313. 10.1016/j.nbd.2004.09.013PubMedCrossRef
37.
Meijer C, de Vries EG, Marmiroli P, Tredici G, Frattola L, Cavaletti G: Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 1999,20(6):883–887.PubMed
38.
Dzagnidze A, Katsarava Z, Makhalova J, Liedert B, Yoon MS, Kaube H, Limmroth V, Thomale J: Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 2007,27(35):9451–9457. 10.1523/JNEUROSCI.0523-07.2007PubMedCrossRef
39.
Ta LE, Espeset L, Podratz J, Windebank AJ: Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006,27(6):992–1002. 10.1016/j.neuro.2006.04.010PubMedCrossRef
40.
Gozdz A, Vashishta A, Kalita K, Szatmari E, Zheng JJ, Tamiya S, Delamere NA, Hetman M: Cisplatin-mediated activation of extracellular signal-regulated kinases 1/2 (ERK1/2) by inhibition of ERK1/2 phosphatases. J Neurochem 2008,106(5):2056–2067.PubMedCentralPubMed
41.
Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ: Paclitaxel-induced neuropathy. Ann Oncol 1995,6(5):489–494.PubMed
42.
Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, Zlotchenko E, Nguyen T, Garcia K, Tonra JR, et al.: Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 1998,43(1):46–55. 10.1002/ana.410430111PubMedCrossRef
43.
Cavaletti G, Tredici G, Braga M, Tazzari S: Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 1995,133(1):64–72. 10.1006/exnr.1995.1008PubMedCrossRef
44.
McKeage MJ, Haddad GG, Ding L, Galettis P, Screnci D, Zhuang L, Baguley BC: Neuroprotective interactions in rats between paclitaxel and cisplatin. Oncol Res 1999,11(6):287–293.PubMed
45.
Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F: Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res 2000,887(2):239–249. 10.1016/S0006-8993(00)02910-3PubMedCrossRef
46.
Jamieson SM, Liu J, Hsu T, Baguley BC, McKeage MJ: Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. Br J Cancer 2003,88(12):1942–1947. 10.1038/sj.bjc.6601012PubMedCentralPubMedCrossRef
47.
Jimenez-Andrade JM, Peters CM, Mejia NA, Ghilardi JR, Kuskowski MA, Mantyh PW: Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat. Neurosci Lett 2006,405(1–2):62–67. 10.1016/j.neulet.2006.06.043PubMedCrossRef
Metadata
Title
Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue
Authors
Stephen MF Jamieson
Joshuan Subramaniam
Johnson J Liu
Nancy N Jong
Virginia Ip
Bronwen Connor
Mark J McKeage
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Pain / Issue 1/2009
Electronic ISSN: 1744-8069
DOI
https://doi.org/10.1186/1744-8069-5-66

Other articles of this Issue 1/2009

Molecular Pain 1/2009 Go to the issue

Research

Involvement of S-nitrosylation of actin in inhibition of neurotransmitter release by nitric oxide

Research

Characterization of NF-kB-mediated inhibition of catechol-O-methyltransferase

Short report

NR2B receptor blockade inhibits pain-related sensitization of amygdala neurons

Research

Reactive oxygen species mediate TNFR1 increase after TRPV1 activation in mouse DRG neurons

Research

An in vivo mouse model of long-term potentiation at synapses between primary afferent C-fibers and spinal dorsal horn neurons: essential role of EphB1 receptor

Research

Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain